Long-term effects of bone morphogenetic protein- based treatments in humans

Journal of Long-Term Effects of Medical Implants

Volumn 20, Issue 4, 2010, Pages 277-293

  Burks, Martin V ^a   Nair, Lakshmi S ^b,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Bone grafts; Bone morphogenetic protein; Clinical trials; Fracture non union; Spinal fusion

Indexed keywords

BONE; GRAFTS; NAILS;

BONE GRAFT; BONE MORPHOGENETIC PROTEINS; CLINICAL TRIAL; FRACTURE NON UNIONS; SPINAL FUSION;

PROTEINS;

ADENOVIRUS VECTOR; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 11; BONE MORPHOGENETIC PROTEIN 12; BONE MORPHOGENETIC PROTEIN 14; BONE MORPHOGENETIC PROTEIN 15; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 8; DRUG CARRIER; GROWTH DIFFERENTIATION FACTOR 6; OSTEOGENIC PROTEIN 1; OSTEOGENIN; PROCOLLAGEN C PROTEINASE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; UNCLASSIFIED DRUG;

BONE DEVELOPMENT; BONE GRAFT; BONE MATRIX; CLINICAL RESEARCH; FRACTURE HEALING; FRACTURE NONUNION; FUSION CAGE; GENE TRANSFER; HUMAN; ILIAC CREST BONE GRAFT; IMPLANT; NONHUMAN; ORTHOPEDIC EQUIPMENT; OSSIFICATION; OSTEOBLAST; PEDICLE SCREW; REVIEW; SPINE FUSION; THERAPY EFFECT; ANIMAL; BONE REGENERATION; CELL CULTURE; DRUG EFFECT; METHODOLOGY; PATHOPHYSIOLOGY; TIME;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; BONE REGENERATION; CELLS, CULTURED; FRACTURE HEALING; FRACTURES, UNUNITED; HUMANS; SPINAL FUSION; TIME FACTORS;

EID: 79959507804     PISSN: 10506934     EISSN: None     Source Type: Journal    
DOI: 10.1615/JLongTermEffMedImplants.v20.i4.30     Document Type: Review

References (70)

1. Rider CC, Mulloy B. Bone morphogenetic protein and growth diff erentiation factor cytokine families and their protein antagonists. Biochem J. 2010;429:1-12.
2. Urist M. Bone: formation by autoinduction. Science. 1965;150:893-9.
3. Schmitt JM, Hwang K, Winn SR, Hollinger JO. Bone morphogenetic proteins: an update on basic biology and clinical relevance. J Orthop Res. 1999;17:269-78.
4. Axelrad TW, Einhorn TA. Bone morphogenetic proteins in orthopaedic surgery. Cytokine Growth Factor Rev. 2009;20:481-8.
5. Alaoui-Ismaili MH, Falb D. Design of second generation therapeutic recombinant bone morphogenetic proteins. Cytokine Growth Factor Rev. 2009;20:501-7.
6. Samartizis D, Khanna N, Shen FH, An HS. Update on bone morphogenetic proteins and their application in spine surgery. J Am Coll Surg. 2005;200:236-48.
7. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS. Bone morphogenetic protein-1: The type I procollagen C-proteinase. Science. 1996;271:360-2.
8. Beaman FD, Bancroft LW, Peterson JJ, Kransdorf MJ. Bone graft materials and synthetic substitutes. Radiol Clin N Am. 2006;44: 451-61.
9. Biase PD, Capanna R. Clinical applications of BMPs. Injury. 2005;365:543-6.
10. Bahamonde ME, Lyons KM. BMP3: To be or not to be a BMP. J Bone Joint Surg Am. 2001;83-A:S56-62.
11. Hino J, Kangawa K, Matsuo H, Nohno T, Nishimatsu S. Bone morphogenetic protein-3 family members and their biological functions. Front Biosci. 2004;9:1520-9.
12. Wozney J. The bone morphogenetic protein family and osteogenesis. Mol Reprod Rev. 1992;32: 160-7.
13. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC. Osteogenic activity of the fourteen types of human bone morphogenetic proteins. J Bone Joint Surg Am. 2003;85-A(8):1544-52.
14. Kang Q, Sun MH, Cheng H, Peng Y, Montag AG, Deyrup AT, Jiang W, Luu HH, Luo J, Szatkowski JP, Vanichakarn P, Park JY, Li Y, Haydon RC, He TC. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther. 2004;11:1312-20.
15. Li JZ, Li H, Sasaki T, Holman D, Beres B, Dumont RJ, Pittman DD, Hankins GR, Helm GA. Osteogenic potential of five diff erent recombinant human bone morphogenetic protein adenoviral vectors in the rat. Gene Ther. 2003;10:1735-43.
16. Wang EA, Israel DI, Kelly S, Luxenberg DP. Bone morphogenetic protein-2 causes commitment and diff erentiation in C3H10T1/2 and 3T3 cells. Growth Factors. 1993;9:57-71.
17. Kanatani M, Sugimoto T, Kaji H, Kobayashi T, Nishiyama K, Fukase M, Kumegawa M, Chihara K. Stimulatory eff ect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res. 1995;10:1681-90.
18. Yeh LC, Tsai AD, Lee JC. Osteogenic protein-1 (OP-1) induces osteoblastic cell diff erentiation of the pluripotent mesenchymal cell line C2C12. J Cell Biochem. 2002;87:292-304.
19. Zhang Y, An HS, Song S, Toofanfard M, Masuda K, Andersson GB, Th onar EJ. Growth factor osteogenic protein-1: diff ering eff ects on cells from three distinct zones. Am J Phys Med Rehabil. 2004;83:515-21.
20. Aspenberg P, Turek T. BMP-2 for intramuscular bone induction: eff ect in squirrel monkeys is dependent on implantation site. Acta Orthop Scand. 1996;67:3-6.
21. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22: 233-41.
22. Seeherman H. The influence of delivery vehicles and their properties on the repair of segmental defects and fractures with osteogenic factors. J Bone Joint Surg Am. 2001;83:79-81.
23. Jeon O, Song SJ, Yang HS, Bhang SH, Kang SW, Sung MA, Lee JH, Kim BS. Long-tem delivery enhances in vivo osteogenic efficacy of bone morphogeneitic protein-2 compared to short-term delivery. Biochem Biophys Res Comm. 2008;369:774-80.
24. Seeherman H, Li R, Bouxsein M, Kim H, Li XJ, Smith-Adaline EA, Aiolova M, Wozney JM. rhBMP-2/calcium phosphate matrix accelerates osteotomy site healing in a nonhuman primate model at multiple treatment times and concentrations. J Bone Joint Surg Am. 2006;88:144-60.
25. Cook SD, Wolfe MW, Salkeld SL, Rueger DC. Eff ect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J Bone Joint Surg Am. 1995;77(5):734-50.
26. Cook SD, Baff es GC, Wolfe MW, Sampath TK, Rueger DC. Recombinant human bone morphogenetic protein-7 induces healing in a canine long bone segmental defect model. Clin Orthop. 1994;301:302-12.
27. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone: biology and clinical applications. J Bone Joint Surg. 2002;84:1032-44.
28. Boden SD, Martin G, Horton WC, Truss TL, Sandhu HS. Laparoscopic anterior spi nal arthrodesis with rhBMP-2 in a titanium interbody threaded cage. J Spinal Disord. 1998;11:95-101.
29. Banc D, Brown A. Estimates and company information. 2001;February
30. Boden SD, Zdeblick TA, Sandhu HS, Helm SE. The use of rhBMP-2 in interbody fusion cages; Definitive evidence of osteoinduction in humans; a preliminary report. Spine. 2000;25:376-81.
31. Schultz DG. P000058 [Internet]. Department of Health and Human Services. Center for Devices and Radiological Health. 2002 [cited 2011 Mar 1]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf/P000058a.pdf.
32. Tillman D. HDE H040004 letter of approval. Department of health and Human Services. Center for Devices and Radiological Health. 2008 [cited 2011 Mar 1]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf4/H040004a.pdf.
33. Burkus JK, Sandhu HS, Gornet MF, Longley MC. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am. 2005;87:1205-12.
34. Slosar PJ, Josey R, Reynolds J. Accelerating lumbar fusions by combining rhBMP-2 with allograft bone: a prospective analysis of interbody fusion rates and clinical outcomes. Spine J. 2007;7:301-7.
35. Haid RW, Branch CL, Alexander JT, Burkus J. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. spine J 2004;4:527-39.
36. Boden SD, Kang J, Sandhu H, Heller JG. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans. Spine. 2002;27:2662-73.
37. Glassman SD, Carreon L, Djurasovic M, Campbell MJ, Puno RM, Johnson JR, Dimar JR. Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J. 2007;7:44-9.
38. Schultz DG. H02008a [Internet]. Department of Health and Human Services. Center for Devices and Radiological Health. 2004b [cited 2011 Mar 1]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf2/H020008a.pdf.
39. Vaccaro AR, Chiba K, Heller JG, Patel TC, Thalgott JS, Truumees E, Fischgrund JS, Craig MR, Berta SC, Wang JC. Bone grafting alternatives in spinal surgery. Spine J. 2002;2:206-15.
40. Vaccaro AR, Anderson G, Patel TC, Fischgrund JS, Truumees E Herkowitz HN, Phillips F, Hilibrand A, Albert TJ, Wetzel T, McCulloch JA. Comparison of OP-1 putty to Iliac crest autograft for posterolateral lumbar arthrodesis. Spine. 2005;30:2709-16.
41. Johnsson R, Stromqvist B, Aspenberg P. Randomized radiostereometric study comparing osteogenic protein-1 and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo award in clinical studies. Spine. 2002;27:2654-61.
42. Kanayama M, Hoshimoto T, Shigenobu K, Yamane S, Bauer TW, Togawa D. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 versus local autograft with ceramic bone substitute. Spine. 2006;31:1067-74.
43. Schultz DG. P000054 [Internet]. Department of Health and Human Services. Center for Devices and Radiological Health. 2004a [cited 2011 Mar 1]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf/P000054a.pdf.
44. Riedal GE, Valentin-Opran A. Clinical evaluation of rhBMP-2/ACS in orthopaedic trauma: a progress report. Orthopedics. 1999;22:663-5.
45. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Börner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, McCoy G, Marsh D, Miller R, Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, Rennie W, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Rüter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T; BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospec tive, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002;84:2123-34.
46. Swiontkowski MF, Aro HT, Donell S, Esterhai JL, Goulet J, Jones A, Kregor PJ, Nordsletten L, Paiement G, Patel A. Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am. 2006;88:1258-65.
47. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, Pollak AN, Golden JD, Valentin-Opran A. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am. 2006;88:1431-41.
48. Kuklo TR, Groth AT, Anderson RC, Frisch HM, Islinger RB. Recombinant human bone morphogenetic protein-2 for grade III open segmental tibial fractures from combat injuries in Iraq. J Bone Joint Surg Br. 2008;90: 1068-72.
49. Schultz DG. HDE, H010002 [Internet]. Department of Health and Human Services. Center for Devices and Radiological Health 2001 [cited 2011 Mar 1]. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf/h010002a.pdf.
50. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S. Osteogenic Protein-1 in the treatment of tibial nonunions: A prospective, randomized clinical trial comparing rhOP-1 with fresh bone autograft. J Bone Joint Surg Am. 2001;83:S151-S8.
51. Mc Kee MD, Schemitsch EH, Waddell JP, Wild L. The treatment of long bone nonunion with rhBMP: results of a prospective pilot study. American Academy of Orthopaedic Surgeons 71st Annual Meeting; San Francisco, CA; March 13, 2004. P242.
52. Ronga M, Baldo F, Zappala G, Cherubino P. Recombinant human bone morphogenetic protein-7 for treatment of long bone non-union: An observational, retrospective, non-randomized study of 105 patients. Injury. 2006;37S: S51-S6.
53. Giannoudis P, Kanakaris N, Dimitriou R, Gill I, Kolimarala V, Montgomery RJ. The synergistic eff ect of autograft and BMP-7 in the treatment of atrophic nonunions. Clin Orthop Relat Res. 2009;467:3239-48.
54. Mroz TE, Wang J, Hashimoto R, Norvell DC. Complications related to osteobiologics use in spine surgery. Spine. 2010;9S:S86-S104.
55. Haider ZS, Hamdy RC, Tabrizian M. Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part B: delivery systems for BMPs in orthopaedic and craniofacial tissue engineering. Biotechnol Lett. 2009;31:1825-35.
56. Schultz DG. FDA Public Health Notification: Life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion [Internet]. Department of Health and Human Services. Center for Devices and Radiological Health Food and Drug Administration. 2004a [cited 2011 Mar 1]. Available from: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062000.htm.
57. Cahill KS, Chi J, Day A, Claus EB. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA. 2009;302:58-66.
58. Ghodadra N, Singh K. Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures. Biologics. 2008;2: 345-54.
59. Smucker J, Rhee J, Singh K, Yoon S, Heller J. Increased swelling complications associated with off -label usage of rhBMP-2 in the anterior cervical spine. Spine. 2006;31:2813-9.
60. Crawford CH, Carreon LY, McGinnis MD, Camphell MJ, Glassman SD. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis. Spine. 2009;34:1390-4
61. Robin BN, Chaput CD, Zeitouni S, Rahm MD, Zerris VA, Sampson HW. Cytokine mediated inflammatory reaction following posterior cervical decompression and fusion associated with recombinant human bone morphogenetic protein-2. Spine. 2010;35:E1350-E4.
62. McClellan JW, Mulconrey DS, Forbes RJ, Fullmer N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech. 2006;19:483-6.
63. Vaidya R, Sethi A, Bartol S, Jacobson M, Coe C, Craig JG. Complications in the use of rh-BMP-2 in PEEK cages for interbody spinal fusions. J Spinal Disord Tech. 2008;21:557-62.
64. Vaidya R, Weir R, Sethi A, Meisterling S, Hakeos W, Wybo CD. Interbody fusion with allograft and rhBMP-2 leads to consistent fusion but early subsidence. J Bone Joint Surg Br. 2007;89:342-5.
65. Tumialan LM, Pan J, Rodts GE, Mummaneni PV. The safety and efficacy of anterior cervical discectomy and fusion with polyetheretherketone spacer and recombinant human bone morphogenetic protein-2: a review of 200 patients. J Neurosurg Spine. 2008;8:529-35.
66. Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP-2 in posterior minimal access interbody fusion: a CT analysis. Spine. 2007;32:2885-90.
67. Kim PD, Ludwig S, Poelstra K, Duggan B, Scalea T, Gelb D. Ectopic bone formation in the pelvis after combined anterior and posterior fusion of the spine with osteogenic protein-1 use: a case report. J Spinal Disord Tech. 2010;23:215-20.
68. Bennett M, Reynolds AS, Dickerman RD. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion [Letter to the Editor]. Spine 2006;31:2029-30.
69. Wong DA, Kumar A, Jatana S. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off -label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 2008;8:1011-8.
70. Huang CJ, Vaccaro AR, Lawrence JP, Hong J, Schellekens H, Alaoui-Ismaili MH, Falb D. Immunogenicity of bone morphogenetic proteins. J Neurosurg Spine. 2009;10:443-51.